Bart Staels Selected Research

2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acid

1/2021	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
1/2016	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
11/2014	The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.
10/2014	GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
12/2013	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
10/2013	Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.
9/2011	Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bart Staels Research Topics

Disease

84	Inflammation (Inflammations) 01/2022 - 01/2002
64	Atherosclerosis 12/2021 - 01/2002
63	Type 2 Diabetes Mellitus (MODY) 01/2022 - 05/2002
49	Insulin Resistance 12/2021 - 05/2002
44	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 02/2002
42	Obesity 01/2022 - 04/2004
39	Dyslipidemias (Dyslipidemia) 12/2020 - 03/2003
26	Non-alcoholic Fatty Liver Disease 01/2022 - 08/2008
23	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 04/2004
17	Fibrosis (Cirrhosis) 01/2022 - 04/2008
16	Body Weight (Weight, Body) 01/2022 - 11/2007
12	Metabolic Diseases (Metabolic Disease) 06/2022 - 12/2005
12	Alcoholic Fatty Liver 06/2022 - 04/2006
12	Hepatocellular Carcinoma (Hepatoma) 04/2014 - 12/2002
11	Hyperglycemia 01/2019 - 04/2005
10	Fatty Liver 06/2022 - 09/2002
10	Hypertriglyceridemia 11/2021 - 02/2005
10	Atherosclerotic Plaque (Atheroma) 06/2017 - 04/2007
9	Neoplasms (Cancer) 01/2021 - 10/2005
9	Weight Gain 03/2020 - 12/2005
7	Stroke (Strokes) 01/2020 - 07/2003
7	Hypertension (High Blood Pressure) 01/2019 - 02/2002
6	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 08/2011
6	Coronary Artery Disease (Coronary Atherosclerosis) 04/2015 - 03/2002
5	Liver Diseases (Liver Disease) 06/2022 - 12/2013
5	Ischemia 05/2021 - 05/2002
5	Infections 01/2021 - 06/2008
5	Hyperinsulinism (Hyperinsulinemia) 01/2018 - 09/2002
4	Aortic Valve Stenosis (Aortic Stenosis) 05/2022 - 03/2015
4	Liver Cirrhosis (Hepatic Cirrhosis) 11/2020 - 12/2013
4	Overweight 11/2018 - 09/2008
4	Glucose Intolerance 01/2018 - 04/2006
4	Acute-Phase Reaction 06/2008 - 04/2004
3	Hemorrhage 08/2022 - 01/2018
3	Disease Progression 01/2021 - 12/2020
3	Weight Loss (Weight Reduction) 01/2021 - 03/2015

Drug/Important Bio-Agent (IBA)

66	Glucose (Dextrose)FDA LinkGeneric 06/2022 - 02/2002
62	LipidsIBA 01/2022 - 01/2002
47	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 12/2021 - 01/2002
47	PPAR alphaIBA 11/2014 - 02/2002
29	Bile Acids and Salts (Bile Acids)IBA 06/2022 - 04/2002
29	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 12/2020 - 09/2003
28	LigandsIBA 06/2022 - 05/2002
27	Triglycerides (Triacylglycerol)IBA 12/2021 - 12/2002
24	CholesterolIBA 03/2020 - 03/2003
23	Fibric Acids (Fibrates)IBA 12/2021 - 12/2002
23	Insulin (Novolin)FDA Link 12/2020 - 05/2004
20	PPAR gammaIBA 06/2008 - 05/2002
14	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 02/2002
14	ThiazolidinedionesIBA 12/2021 - 08/2003
13	Pharmaceutical PreparationsIBA 01/2022 - 04/2005
13	Lipoproteins (Lipoprotein)IBA 12/2021 - 09/2002
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2002
12	Transcription Factors (Transcription Factor)IBA 12/2020 - 09/2002
12	HDL CholesterolIBA 12/2020 - 12/2005
12	CytokinesIBA 01/2019 - 01/2002
11	Messenger RNA (mRNA)IBA 01/2022 - 02/2003
11	ApolipoproteinsIBA 01/2021 - 07/2003
11	Fenofibrate (CiL)FDA LinkGeneric 01/2019 - 12/2002
10	LDL Receptors (LDL Receptor)IBA 01/2021 - 04/2003
9	EnzymesIBA 01/2022 - 07/2003
9	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 10/2004
8	oxidized low density lipoproteinIBA 12/2020 - 12/2006
7	Biological ProductsIBA 04/2021 - 07/2003
7	2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acidIBA 01/2021 - 09/2011
7	HDL LipoproteinsIBA 03/2015 - 03/2003
6	LDL CholesterolIBA 01/2022 - 05/2006
6	Metformin (Glucophage)FDA LinkGeneric 08/2019 - 05/2005
6	Liver X ReceptorsIBA 01/2019 - 03/2003
6	Apolipoprotein E2IBA 01/2016 - 04/2006
6	Rosiglitazone (Avandia)FDA Link 12/2012 - 05/2002
5	CollagenIBA 01/2021 - 04/2006
5	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 03/2015
5	Interleukin-6 (Interleukin 6)IBA 06/2014 - 04/2004
4	von Willebrand FactorIBA 08/2022 - 06/2014
4	Apolipoproteins E (ApoE)IBA 01/2021 - 04/2009
4	LDL Lipoproteins (beta Lipoproteins)IBA 12/2020 - 05/2006
4	Biomarkers (Surrogate Marker)IBA 11/2020 - 11/2007
4	Apolipoprotein A-I (Apolipoprotein A1)IBA 02/2016 - 04/2002
4	Cyclin-Dependent Kinase Inhibitor p16IBA 04/2015 - 11/2005
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2014 - 05/2006
4	Pioglitazone (Actos)FDA Link 03/2013 - 09/2005
4	PPAR deltaIBA 04/2010 - 11/2003
4	GlucocorticoidsIBA 08/2009 - 04/2003
4	NF-kappa B (NF-kB)IBA 08/2008 - 01/2003
4	GW 4064IBA 03/2008 - 02/2003
4	Chenodeoxycholic Acid (Chenix)FDA Link 03/2008 - 02/2003
3	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 06/2022 - 01/2017
3	Liraglutide FDA Link 01/2022 - 01/2019
3	Choline (Choline Chloride)IBA 01/2022 - 12/2013
3	Amyloid (Amyloid Fibrils)IBA 01/2021 - 03/2014
3	Nonesterified Fatty Acids (NEFA)IBA 12/2020 - 08/2005
3	AcidsIBA 12/2020 - 05/2004
3	Glucagon (Glukagon)FDA Link 03/2020 - 05/2015
3	GTP-Binding Proteins (G-Protein)IBA 11/2019 - 12/2016

Therapy/Procedure

27	Therapeutics 06/2022 - 01/2006
4	Bariatric Surgery 01/2022 - 09/2017
4	Drug Therapy (Chemotherapy) 02/2015 - 01/2006
3	Transcatheter Aortic Valve Replacement 05/2022 - 03/2015
3	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2021 - 03/2015